Information about whether talquetamab-tgvs has been included in medical insurance

Talquetamab, as an innovative multiple myeloma treatment that has attracted much attention in recent years, has quickly become one of the most discussed drugs among patients and doctors after it was approved for marketing in China. Although it has been officially launched in my country, it has not yet been included in the national medical insurance catalog, which means that patients need to use this drug at their own expense during medical treatment.

Because it is a newly approved immunotherapy drug, the price system and hospital network status are still in the gradual advancement stage, and a national unified or stable charging standard has not yet been formed. Therefore, there is no clear retail pricing information for the time being. Generally speaking, new drugs entering medical insurance need to go through multiple stages such as drug regulatory approval, real-world feedback, and medical insurance negotiations. However, Taquitutumab, which has just been approved, is obviously still in the early stages of this cycle.

From an international perspective, Taquinutumab is also in the transition period of being gradually included in commercial insurance or temporary access subsidy programs in some European and American countries. Its payment system is usually dynamically adjusted based on factors such as drug positioning, efficacy innovation, and patients' unmet needs. In overseas evaluations, such bispecific antibodies are often regarded as high-value drugs because they have new mechanisms that are different from traditional chemotherapy, proteasome inhibitors and immunomodulators. Therefore, they usually have certain characteristics of innovative drugs in the price system, which also affects their coverage speed in the medical insurance systems of various countries.

Whether it is included in domestic medical insurance usually depends on real-world usage, expert consensus, pharmacoeconomic evaluation, and the medical insurance negotiation process. As a new type of T cell redirecting therapy, if Taquitumab can demonstrate higher safety and controllability in future clinical practice and improve the quality of life of patients after previous treatment, then the possibility of medical insurance negotiation will also increase. However, judging from the current time point, it is still in the preparatory stage of medical insurance negotiation, and its expense reimbursement policy will most likely be promoted in the next two to three years.

Reference materials:https://www.talveyhcp.com/